- Home
- APTV vs INCY Comparison
APTV vs INCY Comparison
Compare APTV & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APTV
- INCY
- Stock Information
- Founded
- APTV 2011
- INCY 1991
- Country
- APTV Switzerland
- INCY United States
- Employees
- APTV N/A
- INCY N/A
- Industry
- APTV Auto Parts:O.E.M.
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- APTV Consumer Discretionary
- INCY Health Care
- Exchange
- APTV Nasdaq
- INCY Nasdaq
- Market Cap
- APTV 14.1B
- INCY 13.4B
- IPO Year
- APTV 1999
- INCY 1993
- Fundamental
- Price
- APTV $66.67
- INCY $72.11
- Analyst Decision
- APTV Buy
- INCY Buy
- Analyst Count
- APTV 19
- INCY 20
- Target Price
- APTV $84.71
- INCY $74.76
- AVG Volume (30 Days)
- APTV 3.3M
- INCY 1.7M
- Earning Date
- APTV 02-06-2025
- INCY 02-10-2025
- Dividend Yield
- APTV N/A
- INCY N/A
- EPS Growth
- APTV N/A
- INCY N/A
- EPS
- APTV 6.96
- INCY 0.15
- Revenue
- APTV $19,713,000,000.00
- INCY $4,241,216,999.00
- Revenue This Year
- APTV $2.96
- INCY $11.81
- Revenue Next Year
- APTV $5.28
- INCY $10.71
- P/E Ratio
- APTV $9.58
- INCY $427.87
- Revenue Growth
- APTV N/A
- INCY 14.76
- 52 Week Low
- APTV $51.47
- INCY $50.35
- 52 Week High
- APTV $85.56
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- APTV 64.93
- INCY 51.77
- Support Level
- APTV $56.22
- INCY $69.75
- Resistance Level
- APTV $67.40
- INCY $72.69
- Average True Range (ATR)
- APTV 1.89
- INCY 2.48
- MACD
- APTV 0.25
- INCY -0.08
- Stochastic Oscillator
- APTV 87.40
- INCY 57.46
About APTV Aptiv PLC
Aptiv Holdings Ltd, formerly Aptiv PLC signal and power solutions segment supplies components and systems that make up a vehicle's electrical system, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, driver-assist technologies, and displays, as well as the development of software for these systems.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.